TICKERNERD
Menu
BCDABCDAHealthcare · Biotechnology

BCDA Stock Forecast: BioCardia, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$0.95
+2.98% on the day

The 2 Wall Street analysts covering BioCardia, Inc. hold a median 12-month price target of $16 — +1536.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 27 Oct 2026 — in the lower half.

Market cap
$13.9M
Ticker Nerd rank
40/ 100
Median analyst target
$16
Analysts covering
2
Revenue$0.0
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$1.7M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
−8.9%
YTD
−24.2%
1Y
−30.8%
From 52W high
−35.6%
From 52W low
+23.0%
$0.77
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioCardia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Growth
63
Revisions
62
Issuance
54
Momentum
44
Volatility
43
Value
28
Accruals
26
Quality
13

Size (89): Smaller than most of the companies we track.

Quality (13): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BCDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26BCDAHigh $25Median $16Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $6Median $16High $25

The green dot is the last close — the median target sits +1536.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
9 June 2026HC Wainwright & Co.ReiteratesBuy$25
9 June 2026HC Wainwright & Co.ReiteratesBuy—
22 Sept 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
28 Oct 2024HC Wainwright & Co.ReiteratesBuy—
21 Aug 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
29 May 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
11 Oct 2023HC Wainwright & Co.ReiteratesBuy—
6 Sept 2023HC Wainwright & Co.MaintainsBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
24 July 2023HC Wainwright & Co.ReiteratesBuy—
21 June 2023HC Wainwright & Co.ReiteratesBuy—
11 May 2023HC Wainwright & Co.ReiteratesBuy—
30 Mar 2023HC Wainwright & Co.ReiteratesBuy—
11 Nov 2022Dawson JamesDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BCDA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BCDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, BioCardia, Inc. returned −30.8% against +13.6% for the S&P 500, dividends included.

BCDA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26BCDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BCDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

BioCardia, Inc. (BCDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
5.1×

Cheaper than 18% of US stocks

EV / EBITDA
−1.4×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1803.2%

Higher than 1% of US stocks

Return on assets
−135.0%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioCardia, Inc. (BCDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioCardia, Inc. has a market value of $13.9M and an enterprise value of $10.1M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$7.8M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$7.5M, after $10K of capital spending.

  • Shares outstanding: 15.1M.

  • Trailing P/E: −0.8×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BioCardia, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

BCDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BCDABioCardia, Inc.$13.9M40
CTXRCitius Pharmaceuticals, Inc.$13.8M23
KTTAPasithea Therapeutics Corp.$13.3M18
DAREDaré Bioscience, Inc.$12.8M31
NCELNewCelX Ltd.$14.6M3
PLURPluri, Inc.$14.7M15
ALLRAllarity Therapeutics, Inc.$14.8M30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioCardia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCDA news & analysis

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter

GlobeNewsWire · 19 Oct 2026positive

BioCardia announced that the FDA accepted its pre-submission package for marketing clearance of the Helix catheter, intended for therapeutic and diagnostic agent delivery. The headline says FDA substantive review and a meeting are expected this quarter.

Why it matters — The FDA’s acceptance marks a regulatory step in BioCardia’s effort to pursue marketing clearance for the Helix catheter.

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

GlobeNewsWire · 7 Oct 2026positive

BioCardia announced that it will present a scientific poster on the CardiAMP HF II trial design at the HFSA Annual Scientific Meeting in Phoenix, October 9–12, 2026. The poster concerns cardiac delivery of autologous minimally processed cell therapy in HFrEF in a multicenter, double-blind randomized trial.

Why it matters — The presentation will share information about the design of a BioCardia clinical trial in heart failure.

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

GlobeNewsWire · 1 Oct 2026neutral

BioCardia reported it has completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health under its Q-Submission program for approval of its Helix Catheter for therapeutic and diagnostic agent delivery to the heart. The filing was announced on October 1, 2026, from BioCardia's headquarters in Sunnyvale, California.

Why it matters — A BCDA watcher would care because this revised FDA pre-submission is a regulatory step in the approval pathway for the Helix Catheter, one of the company's key devices.

BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission

GlobeNewsWire · 23 Sept 2026neutral

BioCardia, Inc. provided an update on near-term milestones, confirming the timing of its FDA Helix Pre-Submission and the PMDA CardiAMP HF Shonin submission in Japan. The update was announced on September 23, 2026.

Why it matters — BCDA watchers would care because the timing of these regulatory submissions in the U.S. and Japan represents key near-term milestones for the company's CardiAMP HF program.

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

BioCardia announced that President and CEO Peter Altman, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. The presentation will cover CardiAMP regulatory and corporate progress.

Why it matters — A BCDA watcher would care because the conference presentation offers a public forum where the company is expected to discuss CardiAMP regulatory and corporate progress.

FAQ

Frequently asked questions about BCDA stock

What is the BCDA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering BioCardia, Inc. have a median 12-month price target of $16, with estimates ranging from $6 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCDA stock a buy right now?

Of the 2 analysts covering BioCardia, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCardia, Inc. 40 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCDA?

As at 27 Oct 2026, BioCardia, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will BCDA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1536.1% from the last close, and Ticker Nerd's factor model ranks BioCardia, Inc. 40 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCDA stock forecast for 2030?

No analyst covering BioCardia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $25 over the next 12 months.

How has BCDA stock performed over the past year?

BioCardia, Inc. returned -30.8% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioCardia, Inc. do?

BioCardia, Inc. Common Stock represents an investment in BioCardia, a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

What is the latest news on BCDA?

The most recent item we track (GlobeNewsWire, 19 Oct 2026): "BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter". BioCardia announced that the FDA accepted its pre-submission package for marketing clearance of the Helix catheter, intended for therapeutic and diagnostic agent delivery. The headline says FDA substantive review and a meeting are expected this quarter.

Company

About BioCardia, Inc.

BioCardia, Inc. Common Stock represents an investment in BioCardia, a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. BioCardia’s current product portfolio centers on autologous and allogeneic cell therapy platforms, including CardiAMP and CardiALLO, which are designed to address unmet needs in heart failure and other serious cardiac conditions. The company also develops enabling medical technologies such as the Helix biotherapeutic delivery system and the Morph line of steerable guide and sheath products, which support precise delivery of therapeutic agents and procedures in cardiovascular care. BioCardia operates in the biotechnology and healthcare markets, where its work combines cell processing, targeted delivery, and regenerative therapy development for clinical use. Headquartered in Sunnyvale, California, BioCardia serves as a specialized participant in the broader field of advanced biologic and device-based cardiovascular treatment solutions.

CEO Dr. Peter A. Altman Ph.D. · 17 employees · United States · https://www.biocardia.com